Literature DB >> 28314274

Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer.

So Yeong Ahn1, Jin Kim1,2, Min A Kim2, Jiwoon Choi2, Woo Ho Kim3,2.   

Abstract

BACKGROUND: Increased expression of hepatocyte growth factor (HGF) and MET proto-oncogene (c-MET) is associated with poor prognosis in various cancer types. Recently, it was reported that the expression of HGF induces resistance to tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor, human epidermal receptor receptor 2, and b-raf proto-oncogene. Here, we investigated the effects of HGF overexpression in gastric cancer cells in the absence or presence of c-MET TKIs.
MATERIALS AND METHODS: The effects of c-MET TKIs in gastric cancer cells with and without c-MET overexpression were determined in gastric cancer cell lines with various cell biology methods.
RESULTS: Compared to the control, cells with induced expression of HGF showed increase in anchorage-independent colony formation (p<0.001). The c-MET TKIs inhibited HGF/c-MET downstream signaling, cell proliferation, migration and invasion, and triggered cell-cycle arrest in Hs746T cells. However, HGF-transfected cells were less affected.
CONCLUSION: c-MET TKIs had inhibitory effects only on cells overexpressing c-MET. Furthermore, overexpression of HGF resulted in resistance to c-MET TKIs through an autocrine manner in gastric cancer cells. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Hepatocyte growth factor; c-MET; gastric neoplasms; tyrosine kinase inhibitor

Mesh:

Substances:

Year:  2017        PMID: 28314274     DOI: 10.21873/anticanres.11426

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

Review 1.  Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement.

Authors:  Xing Huang; Enliang Li; Hang Shen; Xun Wang; Tianyu Tang; Xiaozhen Zhang; Jian Xu; Zengwei Tang; Chengxiang Guo; Xueli Bai; Tingbo Liang
Journal:  Front Cell Dev Biol       Date:  2020-05-06

2.  Blockage of ETS homologous factor inhibits the proliferation and invasion of gastric cancer cells through the c-Met pathway.

Authors:  Meng-Li Gu; Xin-Xin Zhou; Meng-Ting Ren; Ke-Da Shi; Mo-Sang Yu; Wen-Rui Jiao; Ya-Mei Wang; Wei-Xiang Zhong; Feng Ji
Journal:  World J Gastroenterol       Date:  2020-12-21       Impact factor: 5.742

Review 3.  Targeting HGF/c-MET Axis in Pancreatic Cancer.

Authors:  Srinivasa P Pothula; Zhihong Xu; David Goldstein; Romano C Pirola; Jeremy S Wilson; Minoti V Apte
Journal:  Int J Mol Sci       Date:  2020-12-01       Impact factor: 5.923

4.  Human telomerase reverse transcriptase promotes the epithelial to mesenchymal transition in lung cancer cells by enhancing c-MET upregulation.

Authors:  Ram Raj Prasad; Deepak Kumar Mishra; Manoj Kumar; Pramod Kumar Yadava
Journal:  Heliyon       Date:  2021-12-24

5.  Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer.

Authors:  Melanie M Frigault; Aleksandra Markovets; Barrett Nuttall; Kyoung-Mee Kim; Se Hoon Park; Esha A Gangolli; Peter G S Mortimer; Simon J Hollingsworth; Jung Yong Hong; Kyung Kim; Seung Tae Kim; J Carl Barrett; Jeeyun Lee
Journal:  JCO Precis Oncol       Date:  2020-03-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.